Literature DB >> 20808307

Rheumatoid arthritis: Guidelines for RA therapy-avoiding hamartia.

Arthur Kavanaugh1.   

Abstract

Entities:  

Mesh：

Year:  2010        PMID： 20808307     DOI： 10.1038/nrrheum.2010.138

Source DB:  PubMed          Journal:  Nat Rev Rheumatol        ISSN： 1759-4790            Impact factor:   20.543


× No keyword cloud information.
  10 in total

Review 1.  Current evidence for a strategic approach to the management of rheumatoid arthritis with disease-modifying antirheumatic drugs: a systematic literature review informing the EULAR recommendations for the management of rheumatoid arthritis.

Authors:  R Knevel; M Schoels; T W J Huizinga; D Aletaha; G R Burmester; B Combe; R B Landewé; J S Smolen; T Sokka; D M F M van der Heijde
Journal:  Ann Rheum Dis       Date:  2010-05-06       Impact factor: 19.103

Review 2.  Economic aspects of treatment options in rheumatoid arthritis: a systematic literature review informing the EULAR recommendations for the management of rheumatoid arthritis.

Authors:  Monika Schoels; John Wong; David L Scott; Angela Zink; Pamela Richards; Robert Landewé; Josef S Smolen; Daniel Aletaha
Journal:  Ann Rheum Dis       Date:  2010-05-06       Impact factor: 19.103

3.  Therapy: Guidelines in rheumatology: quo vadis?

Authors:  Arthur Kavanaugh
Journal:  Nat Rev Rheumatol       Date:  2009-08       Impact factor: 20.543

4.  American College of Rheumatology 2008 recommendations for the use of nonbiologic and biologic disease-modifying antirheumatic drugs in rheumatoid arthritis.

Authors:  Kenneth G Saag; Gim Gee Teng; Nivedita M Patkar; Jeremy Anuntiyo; Catherine Finney; Jeffrey R Curtis; Harold E Paulus; Amy Mudano; Maria Pisu; Mary Elkins-Melton; Ryan Outman; Jeroan J Allison; Maria Suarez Almazor; S Louis Bridges; W Winn Chatham; Marc Hochberg; Catherine MacLean; Ted Mikuls; Larry W Moreland; James O'Dell; Anthony M Turkiewicz; Daniel E Furst
Journal:  Arthritis Rheum       Date:  2008-06-15

5.  Updated consensus statement on biological agents for the treatment of rheumatic diseases, 2009.

Authors:  D E Furst; E C Keystone; R Fleischmann; P Mease; F C Breedveld; J S Smolen; J R Kalden; J Braun; B Bresnihan; G R Burmester; F De Benedetti; T Dörner; P Emery; A Gibofsky; A Kavanaugh; B Kirkham; M H Schiff; J Sieper; N Singer; P L C M Van Riel; M E Weinblatt; M H Weisman; K Winthrop
Journal:  Ann Rheum Dis       Date:  2010-01       Impact factor: 19.103

Review 6.  Current evidence for the management of rheumatoid arthritis with biological disease-modifying antirheumatic drugs: a systematic literature review informing the EULAR recommendations for the management of RA.

Authors:  J L Nam; K L Winthrop; R F van Vollenhoven; K Pavelka; G Valesini; E M A Hensor; G Worthy; R Landewé; J S Smolen; P Emery; M H Buch
Journal:  Ann Rheum Dis       Date:  2010-05-06       Impact factor: 19.103

Review 7.  Current evidence for the management of rheumatoid arthritis with synthetic disease-modifying antirheumatic drugs: a systematic literature review informing the EULAR recommendations for the management of rheumatoid arthritis.

Authors:  Cécile Gaujoux-Viala; Josef S Smolen; Robert Landewé; Maxime Dougados; Tore K Kvien; Emilio Martin Mola; Marieke Scholte-Voshaar; Piet van Riel; Laure Gossec
Journal:  Ann Rheum Dis       Date:  2010-05-06       Impact factor: 19.103

8.  Variation in the net benefit of aggressive cardiovascular risk factor control across the US population of patients with diabetes mellitus.

Authors:  Justin W Timbie; Rodney A Hayward; Sandeep Vijan
Journal:  Arch Intern Med       Date:  2010-06-28

Review 9.  EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs.

Authors:  Josef S Smolen; Robert Landewé; Ferdinand C Breedveld; Maxime Dougados; Paul Emery; Cecile Gaujoux-Viala; Simone Gorter; Rachel Knevel; Jackie Nam; Monika Schoels; Daniel Aletaha; Maya Buch; Laure Gossec; Tom Huizinga; Johannes W J W Bijlsma; Gerd Burmester; Bernard Combe; Maurizio Cutolo; Cem Gabay; Juan Gomez-Reino; Marios Kouloumas; Tore K Kvien; Emilio Martin-Mola; Iain McInnes; Karel Pavelka; Piet van Riel; Marieke Scholte; David L Scott; Tuulikki Sokka; Guido Valesini; Ronald van Vollenhoven; Kevin L Winthrop; John Wong; Angela Zink; Désirée van der Heijde
Journal:  Ann Rheum Dis       Date:  2010-05-05       Impact factor: 19.103

10.  Effect of certolizumab pegol with methotrexate on home and work place productivity and social activities in patients with active rheumatoid arthritis.

Authors:  Arthur Kavanaugh; Josef S Smolen; Paul Emery; Oana Purcaru; Edward Keystone; Lance Richard; Vibeke Strand; Ronald F van Vollenhoven
Journal:  Arthritis Rheum       Date:  2009-11-15
  10 in total
  1 in total

1.  Clinical guidelines: Addressing comorbidities in systemic inflammatory disorders.

Authors:  Tristan Boyd; Arthur Kavanaugh
Journal:  Nat Rev Rheumatol       Date:  2015-09-22       Impact factor: 20.543
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.